Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 7, 2017

Primary Completion Date

December 14, 2017

Study Completion Date

December 14, 2017

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Reference capsule GDC-0134

Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.

DRUG

Prototype capsule GDC-0134

Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.

DRUG

rabeprazole

Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.

Trial Locations (1)

NG11 6JS

Quotient Clinical Ltd, Clinical Research Unit, Nottingham

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Quotient Clinical

OTHER

lead

Genentech, Inc.

INDUSTRY

NCT03237741 - Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants | Biotech Hunter | Biotech Hunter